Ensure patent venous access prior to administration of Kaviase au Bleu de Methylene (Methylene Blue).If methemoglobin level remains above 30% or if clinical symptoms persist, give a repeat dose of up to 1 mg/kg one hour after the first dose.Administer 1 mg/kg intravenously over 5-30 minutes.Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials. This indication is approved under accelerated approval. Kaviase au Bleu de Methylene (Methylene Blue) (methylene blue) is an oxidation-reduction agent indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia. Kaviase au Bleu de Methylene (Methylene Blue) is indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia. Avoid concomitant use of Kaviase au Bleu de Methylene (Methylene Blue) with selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and monoamine oxidase inhibitors ( 5.1, 7.1). Kaviase au Bleu de Methylene (Methylene Blue) may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs. WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS
0 Comments
Leave a Reply. |